Options traders are positioned aggressively bullish on QURE. Short sellers are building the opposite view. With earnings due July 31, the two camps are setting up a direct confrontation.
The put-call ratio on QURE sat at 0.14 mid-week — near the 52-week low of 0.12. Calls outnumber puts by roughly 7-to-1. The 20-day average PCR is 0.17, so this week's reading reflects a genuine tilt, not the baseline. Options traders are making a directional bet. July 31 is the focal point.
The stock has form around earnings. The May print delivered a +10.3% one-day move. The five-day return after that event was +40.7%. That kind of post-earnings momentum likely explains some of the call demand.
Short interest rose 13.2% in a week to 18.2% of free float. That is a meaningful increase at an already elevated level. Bears added roughly 1.3 million shares short in the past five trading sessions alone.
The borrow market tells an interesting side story. Cost to borrow actually fell 67% over the week to 0.43% — cheap by any measure. Availability sits at 550%. There is no shortage of shares to borrow. Shorts are not being squeezed out of their positions. They are adding freely.
That combination — rising short interest, falling borrow cost, abundant availability — suggests organised, low-friction short-selling rather than a disorderly positioning event.
The analyst upgrade cycle that began June 18 continued this week. HC Wainwright raised its target from $50 to $80 on June 29. Mizuho lifted its target from $35 to $68 on June 25. Both maintained bullish ratings.
This follows Barclays' upgrade to Overweight (target $65) and target raises from Leerink Partners ($70), RBC Capital ($65), and Goldman Sachs ($46) — all on June 18. The consensus mean target now sits at $54.11 against a last close of $47.51.
Goldman remains the holdout at Neutral. Its target of $46 is now below the current price. That gap matters — it gives the bear case a credible anchor from a major firm.
As noted in the June 24 article, CEO Matthew Kapusta has been a consistent seller into the rally. He sold a further 28,716 shares on June 25 for approximately $1.44 million, adding to over $6 million in sales across June 17–18. Net 90-day insider value is +$14.5 million, but that reflects earlier accumulation. The recent pattern is one-directional: the CEO is selling.
Three things converge on July 31: earnings, options expiry positioning, and a short base at 18.2% of float. The analyst bull case centres on AMT-130 pipeline progress. The bear case, backed by Goldman's sub-price target, is that a clinical-stage company with no revenue and mounting cash burn is priced for perfection. The options market is betting the bulls are right. The short sellers disagree.
See the live data behind this article on ORTEX.
Open QURE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
